Header cover image

New Zealand (NZX) Pharma Industry Analysis

UpdatedJul 22, 2024
DataAggregated Company Financials
  • 7D-0.3%
  • 3M-2.3%
  • 1Y-21.6%
  • YTDn/a

Over the last 7 days, the Pharma industry has dropped 4.1%, driven by a pullback from Rua Bioscience of 29%. However, the industry is down 25% over the past year. Earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the New Zealand Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 22 Jul 2024NZ$353.7mNZ$207.5m-NZ$1,274,813.0027.1x-277.4x1.7x
Wed, 19 Jun 2024NZ$392.1mNZ$208.5m-NZ$10,082,906.0029.2x-38.9x1.9x
Fri, 17 May 2024NZ$367.5mNZ$186.8m-NZ$15,744,906.0027.3x-23.3x2x
Sun, 14 Apr 2024NZ$408.5mNZ$186.8m-NZ$15,744,906.0031x-25.9x2.2x
Tue, 12 Mar 2024NZ$404.6mNZ$186.8m-NZ$15,744,906.0030x-25.7x2.2x
Thu, 08 Feb 2024NZ$489.7mNZ$185.9mNZ$4.6m36.9x105.7x2.6x
Sat, 06 Jan 2024NZ$467.2mNZ$185.9mNZ$4.6m34.5x100.8x2.5x
Mon, 04 Dec 2023NZ$453.2mNZ$168.1mNZ$4.4m33.1x103.9x2.7x
Wed, 01 Nov 2023NZ$457.8mNZ$167.6mNZ$3.3m32.9x136.9x2.7x
Fri, 29 Sep 2023NZ$473.0mNZ$167.6mNZ$3.3m33.5x141.4x2.8x
Sun, 27 Aug 2023NZ$495.6mNZ$167.6m-NZ$4,073,109.0035.4x-121.7x3x
Tue, 25 Jul 2023NZ$520.3mNZ$167.6m-NZ$4,073,109.0036.4x-127.7x3.1x
Thu, 22 Jun 2023NZ$528.6mNZ$167.6m-NZ$4,073,109.0035.2x-129.8x3.2x
Sat, 20 May 2023NZ$473.1mNZ$150.7mNZ$1.1m21.5x437.3x3.1x
Mon, 17 Apr 2023NZ$470.9mNZ$150.7mNZ$1.1m20.9x435.2x3.1x
Wed, 15 Mar 2023NZ$510.7mNZ$150.7mNZ$1.1m22.5x467x3.4x
Fri, 10 Feb 2023NZ$532.5mNZ$153.3mNZ$1.2m23.4x440.5x3.5x
Sun, 08 Jan 2023NZ$515.4mNZ$153.3mNZ$1.2m22.9x426.3x3.4x
Tue, 06 Dec 2022NZ$518.8mNZ$153.3mNZ$1.2m23x429.1x3.4x
Thu, 03 Nov 2022NZ$520.6mNZ$143.0mNZ$3.9m19.7x133.8x3.6x
Sat, 01 Oct 2022NZ$478.8mNZ$143.0mNZ$3.9m17.4x123.1x3.3x
Mon, 29 Aug 2022NZ$506.1mNZ$142.3mNZ$8.0m18.2x63.4x3.6x
Wed, 27 Jul 2022NZ$572.9mNZ$141.0mNZ$9.7m20.8x59x4.1x
Fri, 24 Jun 2022NZ$524.0mNZ$141.0mNZ$9.7m19.3x53.9x3.7x
Sun, 22 May 2022NZ$489.4mNZ$130.2mNZ$920.3k31.6x531.8x3.8x
Tue, 19 Apr 2022NZ$554.5mNZ$130.2mNZ$920.3k35.9x602.5x4.3x
Thu, 17 Mar 2022NZ$555.7mNZ$130.2mNZ$2.2m36x255.2x4.3x
Sat, 12 Feb 2022NZ$619.6mNZ$129.0m-NZ$95,598.00n/a-6481.6x4.8x
Mon, 10 Jan 2022NZ$668.4mNZ$129.0m-NZ$95,598.0044.4x-6991.8x5.2x
Wed, 08 Dec 2021NZ$664.2mNZ$129.0m-NZ$95,598.00n/a-6947.7x5.1x
Fri, 05 Nov 2021NZ$699.7mNZ$124.1m-NZ$281,598.00101.6x-2484.9x5.6x
Sun, 03 Oct 2021NZ$639.8mNZ$124.1m-NZ$281,598.00102.8x-2271.9x5.2x
Tue, 31 Aug 2021NZ$630.3mNZ$124.7m-NZ$281,598.00100.9x-2238.4x5.1x
Price to Earnings Ratio


Total Market Cap: NZ$668.2mTotal Earnings: -NZ$281,598.00Total Revenue: NZ$124.7mTotal Market Cap vs Earnings and Revenue0%0%0%
New Zealand Pharma Industry Price to Earnings3Y Average -746x202220232024
Current Industry PE
  • Investors are pessimistic on the New Zealander Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 3.5x is higher than the industry's current PS ratio of 1.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 19% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Comparison

How does New Zealand Pharma compare with similar industries?

NZ Market1.77%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GFI Greenfern IndustriesNZ$0.03650.0%
BLT BLIS TechnologiesNZ$0.0176.3%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News



BLIS Technologies







Greenfern Industries







Rua Bioscience